Technology | Ablation Systems | August 15, 2016

FDA Clears Latest Generation Irrigated Ablation Catheter With Force Sensing Technology

Thermocool Smarttouch SF Catheter is the only device to combine contact force technology with a porous tip designed to optimize efficiency in atrial fibrillation ablations

 

Biosense Webster, Smarttouch SF, ablation catheter, AF, Afib, Atrial fibrillation treatment

August 15, 2016 — The U.S. Food and Drug Administration has granted market approval for the Biosense Webster Thermocool Smarttouch SF Catheter. The catheter is the only approved device pairing contact force technology with a porous tip irrigation designed to optimize efficiency. This optimizes efficiency by providing uniform cooling at half the flow rate of earlier generation irrigated catheters, easing the fluid management process. The electrophysiology (EP) device is designed to treat patients with Atrial fibrillation (Afib).

"The Thermocool Smarttouch SF Catheter is an exciting development for patients and electrophysiologists alike, addressing many of the challenges faced using earlier technologies," said Larry A. Chinitz, M.D., professor of medicine and cardiac electrophysiology and clinical director of the Leon Charney Division of Cardiology at the New York University School of Medicine. "With its combination of contact force technology and porous tip design, the device integrates two important features in a way that will help physicians like myself improve outcomes for patients being treated with catheter ablation."

Clinical data has demonstrated the safety of the device when used to treat drug refractory paroxysmal atrial fibrillation. The SMART-AF trial, a multicenter, prospective study of the earlier generation Thermocool Smarttouch technology, revealed no unanticipated adverse events and demonstrated a success rate of greater than 80 percent, with increased stability within the contact force range.[1] Success is defined as freedom from any atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) 12 months post procedure when operator remained in the preset contact force range. 

Further sub-analysis showed that when the contact force was within investigator-selected range ≥ 85% of time, success was increased by 21% to 88% (≥ 85%: n = 32; < 85%: n = 73). The more recent SMART-SF study, which tested the newest generation Thermocool Smarttouch SF Catheter, demonstrated excellent safety results as well.[2] The study found an 18.7 percent reduction in overall procedure time and a 14.2 percent reduction in overall ablation time when compared to the SMART-AF study. It also demonstrated a 55.2 percent reduction in total fluoroscopy time, limiting radiation exposure to patients.[3]

"The Thermocool Smarttouch SF Catheter represents a significant advancement for the clinical community," said Dr. Andrea Natale, Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas. "Conducted trials, including the SMART-AF and SMART-SF studies, have shown Biosense Webster technology enables physicians to achieve targeted stability in the defined contact force range, leading to shorter procedure times and enhanced results without compromising safety."

The catheter is seamlessly integrated with the Carto 3 System, which combines contact force technology, 3-D mapping and advanced navigation capabilities to provide active measurement of stable contact force and catheter tip location.

The Thermocool Smarttouch SF Catheter is available for commercial sale in the United States and Europe.

 

Atrial Fibrillation and Contact Force Therapy

Afib is the most prevalent heart rhythm disorder and a leading cause of stroke among people 65 years and older. An estimated 3 million people in the United States and 20 million worldwide are affected by Afib, and its prevalence is projected to increase significantly as the population ages.[4] Afib is a progressive disease and increases in severity and frequency as patients get older. Left untreated, it can lead to heart valve disease, sleep apnea, chronic fatigue, congestive heart failure and stroke. The public health implications of Afib are a growing concern because those with Afib are at an increased risk of morbidity and mortality, as well as a reduced quality of life. It is estimated to be responsible for 88,000 deaths and $16 billion in additional costs to the U.S. healthcare system on an annual basis.[5]

During catheter ablation, doctors insert a therapeutic catheter through a small incision in the groin, where it is then weaved up to the heart through a blood vessel. Once it reaches the left upper chamber of the heart (atrium), radiofrequency energy is delivered to the heart wall to create lesions that block faulty electrical impulses that can cause heart rhythm disorders.

Watch the VIDEO "Current State of Atrial Fibrillation Technologies," an interview with Dr. Hugh Calkins at HRS 2017.

For more information: www.biosensewebster.com

 

 

References:

1. Natale A, et al. "SMART-AF trial." J Am Coll Cardiol. 2014; 64(7): 647-656. Biosense Webster, Inc. Final Clinical Report, October 2014.
1. THERMOCOOL SMARTTOUCH Catheter IFU (M-5276-693/694) 
2. Prospective Safety Assessment of the THERMOCOOL SMARTTOUCH SF Family of Contact Force Sensing Catheters for the Radiofrequency Ablation Treatment of Drug Refractory Symptomatic PAF (Smart-SF). Biosense Webster Inc. Final Clinical Report, January 2016
3. Compared to SMART-AF study.
4. Naccarelli GV, Varker H, Lin J, Schulman KL. "Increasing prevalence of atrial fibrillation and flutter in the United States." Am J Cardiol.2009;104:1534-1539.
5. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. "Estimation of total incremental health care costs in patients with atrial fibrillation in the United States." Circ Cardiovasc Qual Outcomes 2011;4:313–320.

Related Content

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies| December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio.  Image courtesy of Joe Carfora.

Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio. 
Image courtesy of Joe Carfora.

News | November 25, 2017
November 25, 2017 — Sitting in, or standing close to the charging port of a Tesla electric vehicle did not trigger a
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization
News | Pacemakers| November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation| November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was the No. 1 most popular article on DAIC in October.

Feature | November 03, 2017 | Dave Fornell
November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Card
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation| November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
Overlay Init